Novavax Inc vs TeraWulf Inc — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while TeraWulf Inc trades at $20.11 (market cap $9.35B). The key difference: TeraWulf Inc is far larger — about 7.2× Novavax Inc's market cap, and TeraWulf Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | WULF | |
|---|---|---|
Market Cap | $1.30B | $9.35B |
Sector | Health | Technology |
52-Week High | $11.19 | $28.98 |
52-Week Low | $6.22 | $4.76 |
Enterprise Value | $800.50M | $12.03B |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
No Aura AI signal available yet.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →